US5994103A
(en)
*
|
1995-06-02 |
1999-11-30 |
Human Genome Science, Inc. |
Human stanniocalcin-alpha
|
FR2751989B1
(fr)
*
|
1996-08-01 |
1998-10-30 |
Soc D Rech Et De Dev En Activa |
Methode d'identification de cellules eucaryotes par fixation desdites cellules sur un support et support pour mettre en oeuvre ladite methode
|
US6544797B1
(en)
|
1997-04-09 |
2003-04-08 |
Biosite Diagnostics, Inc. |
Compositions and methods for inhibiting light-induced inactivation of biological reagents
|
US6830731B1
(en)
*
|
1998-01-05 |
2004-12-14 |
Biosite, Inc. |
Immunoassay fluorometer
|
US6392894B1
(en)
|
1998-01-05 |
2002-05-21 |
Biosite Incorporated |
Media carrier for an assay device
|
US6096726A
(en)
*
|
1998-03-11 |
2000-08-01 |
Surface Solutions Laboratories Incorporated |
Multicomponent complex for use with substrate
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
US20040121350A1
(en)
*
|
2002-12-24 |
2004-06-24 |
Biosite Incorporated |
System and method for identifying a panel of indicators
|
US7632647B2
(en)
|
2001-04-13 |
2009-12-15 |
Biosite Incorporated |
Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
|
US7524635B2
(en)
*
|
2003-04-17 |
2009-04-28 |
Biosite Incorporated |
Methods and compositions for measuring natriuretic peptides and uses thereof
|
US7713705B2
(en)
*
|
2002-12-24 |
2010-05-11 |
Biosite, Inc. |
Markers for differential diagnosis and methods of use thereof
|
US20030219734A1
(en)
*
|
2001-04-13 |
2003-11-27 |
Biosite Incorporated |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
US20040203083A1
(en)
*
|
2001-04-13 |
2004-10-14 |
Biosite, Inc. |
Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
|
US20040126767A1
(en)
*
|
2002-12-27 |
2004-07-01 |
Biosite Incorporated |
Method and system for disease detection using marker combinations
|
US20030199000A1
(en)
*
|
2001-08-20 |
2003-10-23 |
Valkirs Gunars E. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
US20040253637A1
(en)
*
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
DE60233301D1
(de)
|
2001-05-04 |
2009-09-24 |
Biosite Inc |
Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
|
ATE445160T1
(de)
*
|
2001-08-20 |
2009-10-15 |
Biosite Inc |
Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
|
US20040219509A1
(en)
*
|
2001-08-20 |
2004-11-04 |
Biosite, Inc. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
WO2004094460A2
(en)
|
2003-04-17 |
2004-11-04 |
Ciphergen Biosystems, Inc. |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
JP2007518062A
(ja)
*
|
2003-09-29 |
2007-07-05 |
バイオサイト インコーポレイテッド |
敗血症を診断する方法および診断するための組成物
|
ATE449337T1
(de)
|
2003-12-12 |
2009-12-15 |
Inverness Medical Switzerland |
Assay
|
US7022492B2
(en)
*
|
2003-12-15 |
2006-04-04 |
Dade Behring Inc. |
Ecstasy haptens and immunogens
|
US6991911B2
(en)
*
|
2003-12-15 |
2006-01-31 |
Dade Behring Inc. |
Assay for entactogens
|
US20050130243A1
(en)
*
|
2003-12-15 |
2005-06-16 |
Zheng Yi F. |
Assay for entactogens
|
US7037669B2
(en)
*
|
2004-03-22 |
2006-05-02 |
Dade Behring Inc. |
Assays for amphetamine and methamphetamine using stereospecific reagents
|
US7115383B2
(en)
*
|
2004-03-22 |
2006-10-03 |
Dade Behring Inc. |
Assays for amphetamine and methamphetamine
|
US20060105419A1
(en)
*
|
2004-08-16 |
2006-05-18 |
Biosite, Inc. |
Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
|
JP4581571B2
(ja)
*
|
2004-09-06 |
2010-11-17 |
富士ゼロックス株式会社 |
粒子のマレイミジル基量を測定する定量方法
|
EP1794588A2
(de)
*
|
2004-09-09 |
2007-06-13 |
Biosite Incorporated |
Verfahren und zusammensetzungen zur messung von hunde-bnp und verwendungen davon
|
US20060084184A1
(en)
*
|
2004-10-19 |
2006-04-20 |
Renovar Incorporated |
Reagents for urine-based immunological assays
|
US20080050832A1
(en)
*
|
2004-12-23 |
2008-02-28 |
Buechler Kenneth F |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
WO2006078813A2
(en)
*
|
2005-01-21 |
2006-07-27 |
Biosite Incorporated |
Arginine analogs, and methods for their synthesis and use
|
CA2610910A1
(en)
*
|
2005-06-09 |
2006-12-21 |
Paul H. Mcpherson |
Methods and compositions for the diagnosis of venous thromboembolic disease
|
WO2007028070A2
(en)
*
|
2005-08-30 |
2007-03-08 |
Biosite, Inc. |
Use of soluble flt-1 and its fragments in cardiovascular conditions
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
EP2005168A4
(de)
*
|
2006-03-09 |
2009-05-20 |
Biosite Inc |
Verfahren und zusammensetzung zur diagnose von krankheiten der aorta
|
US20080118924A1
(en)
*
|
2006-05-26 |
2008-05-22 |
Buechler Kenneth F |
Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
ATE528411T1
(de)
|
2006-06-07 |
2011-10-15 |
Otago Innovation Ltd |
Diagnoseverfahren und -marker
|
CN101495868A
(zh)
*
|
2006-07-28 |
2009-07-29 |
博适公司 |
利用磁性颗粒进行受体结合试验的装置和方法
|
DK2089722T3
(en)
|
2006-09-07 |
2018-01-22 |
Otago Innovation Ltd |
BIOMARKET FOR EARLY DETECTION OF ACUTE HEART DISORDERS
|
EP2095106B1
(de)
*
|
2006-11-14 |
2013-03-20 |
Alere San Diego, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenarterienstenose
|
WO2008060607A2
(en)
*
|
2006-11-14 |
2008-05-22 |
Biosite Incorporated |
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
|
US8221995B2
(en)
*
|
2007-03-23 |
2012-07-17 |
Seok-Won Lee |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
US20090004755A1
(en)
*
|
2007-03-23 |
2009-01-01 |
Biosite, Incorporated |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
US7903970B2
(en)
*
|
2007-03-30 |
2011-03-08 |
Georgia Tech Research Corporation |
Optical network evaluation systems and methods
|
US20090053832A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Link William F |
Simultaneous assay for determining drugs
|
US7947465B2
(en)
*
|
2007-08-20 |
2011-05-24 |
Bio-Rad Laboratories, Inc. |
Simultaneous assay for determining drugs
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US8507209B2
(en)
|
2008-03-12 |
2013-08-13 |
Otago Innovation Limited |
Biomarkers
|
EP2265641B1
(de)
|
2008-03-12 |
2018-01-24 |
Otago Innovation Limited |
Biomarker
|
NZ610356A
(en)
|
2008-08-28 |
2015-03-27 |
Astute Medical Inc |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CN102187219B
(zh)
|
2008-08-29 |
2015-08-05 |
阿斯图特医药公司 |
用于诊断和预后肾损伤和肾衰竭的方法和组合物
|
CN104391116B
(zh)
|
2008-10-21 |
2016-09-07 |
阿斯图特医药公司 |
用于诊断和预后肾损伤和肾衰竭的方法和组合物
|
EP2767833A3
(de)
|
2008-10-21 |
2014-12-17 |
Astute Medical, Inc. |
Verfahren und Zusammensetzungen zur Diagnose und Prognose von Nierenläsion und Niereninsuffizienz
|
BRPI0922021A2
(pt)
|
2008-11-10 |
2019-09-24 |
Astute Medical Inc |
método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
|
EP2364370B1
(de)
|
2008-11-22 |
2014-09-03 |
Astute Medical, Inc. |
Verfahren zur prognose von akuter niereninsuffizienz
|
WO2010065944A1
(en)
*
|
2008-12-05 |
2010-06-10 |
Serametrix |
Autoantibody detection systems and methods
|
AU2010210540B2
(en)
|
2009-02-06 |
2015-06-18 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and failure
|
CA2751430A1
(en)
|
2009-02-06 |
2010-08-12 |
Astute Medical, Inc. |
Diagnosis and prognosis of renal injury and renal failure
|
CA2767616A1
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
WO2011017614A1
(en)
|
2009-08-07 |
2011-02-10 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP2462440B1
(de)
|
2009-08-07 |
2017-05-17 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
|
AU2010286559B2
(en)
|
2009-08-28 |
2015-01-22 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CN105004864B
(zh)
|
2009-09-18 |
2017-11-03 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断及预后方法和组合物
|
NZ599105A
(en)
|
2009-09-21 |
2014-08-29 |
Astute Medical Inc |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2779905A1
(en)
|
2009-11-07 |
2011-05-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US10324093B2
(en)
|
2009-11-07 |
2019-06-18 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
ES2562832T3
(es)
*
|
2009-12-08 |
2016-03-08 |
Abbvie Deutschland Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
|
KR102003258B1
(ko)
|
2009-12-20 |
2019-07-24 |
아스튜트 메디컬 인코포레이티드 |
신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
|
WO2011097541A2
(en)
|
2010-02-05 |
2011-08-11 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2788826C
(en)
|
2010-02-05 |
2023-09-26 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2789147A1
(en)
|
2010-02-05 |
2011-08-11 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2011162819A1
(en)
|
2010-06-23 |
2011-12-29 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
AU2011220413B2
(en)
|
2010-02-26 |
2015-07-23 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
JP5786020B2
(ja)
|
2010-04-16 |
2015-09-30 |
アボットジャパン株式会社 |
関節リウマチを診断する方法および試薬
|
EP2899545B1
(de)
|
2010-06-23 |
2018-08-22 |
Astute Medical, Inc. |
Verfahren zur diagnose und prognose von nierenläsion und niereninsuffizienz
|
WO2011162821A1
(en)
|
2010-06-23 |
2011-12-29 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CN103140498B
(zh)
|
2010-07-19 |
2017-05-17 |
奥塔哥创新有限公司 |
信号生物标志物
|
US10557856B2
(en)
|
2010-09-24 |
2020-02-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Biomarkers of renal injury
|
ES2619617T3
(es)
|
2010-09-24 |
2017-06-26 |
Astute Medical, Inc. |
Procedimientos para la evaluación de una lesión renal utilizando ácido hialurónico
|
US20130316370A1
(en)
|
2010-10-07 |
2013-11-28 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US8795975B2
(en)
|
2010-11-29 |
2014-08-05 |
Alere San Diego, Inc. |
Methods and compositions for diagnosis and risk prediction in heart failure
|
US20140147864A1
(en)
|
2011-01-08 |
2014-05-29 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP2668497B1
(de)
|
2011-01-26 |
2020-03-25 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Urinbiomarker zur vorhersage der erholung nach einer akuten nierenverletzung: proteomik
|
WO2012103450A2
(en)
|
2011-01-29 |
2012-08-02 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CN103620407B
(zh)
*
|
2011-06-29 |
2016-09-21 |
美迪恩斯生命科技株式会社 |
非特异性反应抑制剂、非特异性反应抑制方法及试剂盒
|
PL2748605T4
(pl)
|
2011-08-26 |
2019-08-30 |
Astute Medical, Inc. |
Sposoby i kompozycje do diagnozowania i prognozowania uszkodzenia nerek i niewydolności nerek
|
EP3282257A1
(de)
|
2011-11-22 |
2018-02-14 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
|
EP2788759B1
(de)
|
2011-12-08 |
2019-02-20 |
Astute Medical, Inc. |
Verfahren und verwendungen zur diagnose von nierenverletzungen und niereninsuffizienz
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP3800200A1
(de)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
LT2807192T
(lt)
|
2012-01-27 |
2018-07-25 |
AbbVie Deutschland GmbH & Co. KG |
Kompozicijos ir būdai, skirti ligų, susijusių su neuritų degeneracija, diagnostikai ir gydymui
|
WO2013130594A1
(en)
|
2012-02-27 |
2013-09-06 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
RU2014141059A
(ru)
|
2012-03-13 |
2016-04-27 |
Эббви Инк. |
Способ отбора или идентификации субъекта для терапии антагонистом v1b
|
DK2828282T3
(en)
|
2012-03-20 |
2018-03-05 |
Otago Innovation Ltd |
Biomarkers
|
EP3699591A1
(de)
|
2012-04-02 |
2020-08-26 |
Astute Medical, Inc. |
Verfahren zur diagnose und prognose von sepsis
|
US9733261B2
(en)
|
2012-04-24 |
2017-08-15 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
|
EP3572809A1
(de)
|
2012-07-23 |
2019-11-27 |
Astute Medical, Inc. |
Verfahren zur diagnose von sepsis
|
US20150241415A1
(en)
|
2012-08-11 |
2015-08-27 |
Astute Medical, Inc. |
Evaluating renal injury using hyaluronic acid
|
TR201807542T4
(tr)
|
2013-01-17 |
2018-06-21 |
Astute Medical Inc |
Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler.
|
CN105916860A
(zh)
|
2013-03-14 |
2016-08-31 |
美艾利尔圣地亚哥公司 |
6-单乙酰吗啡类似物的合成和使用方法
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
EP3004873B1
(de)
|
2013-06-05 |
2024-01-24 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
|
EP3632467B1
(de)
|
2013-06-07 |
2023-09-27 |
Duke University |
Inhibitoren des komplementfaktors h
|
KR20160039682A
(ko)
|
2013-08-07 |
2016-04-11 |
아스튜트 메디컬 인코포레이티드 |
생물학적 샘플에서 개선된 성능을 가지는 timp2에 대한 검정
|
CN112870202A
(zh)
|
2013-08-23 |
2021-06-01 |
里亚塔医药公司 |
使用甲基巴多索隆或其类似物治疗和预防肾病的方法
|
WO2015031626A1
(en)
|
2013-08-28 |
2015-03-05 |
Abbvie Inc. |
Soluble cmet assay
|
CN105556308B
(zh)
|
2013-09-20 |
2018-05-29 |
阿斯图特医药公司 |
用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
|
CA2929547C
(en)
|
2013-11-06 |
2023-02-28 |
Astute Medical, Inc. |
Assays for igfbp7 having improved performance in biological samples
|
CN105917229B
(zh)
|
2013-12-03 |
2019-04-26 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断和预后的方法和组合物
|
CN106795550A
(zh)
|
2013-12-30 |
2017-05-31 |
促进军事医学的亨利·M·杰克逊基金会公司 |
与前列腺癌有关的基因组重排和使用所述基因组重排的方法
|
EP3825417A3
(de)
|
2014-05-22 |
2021-09-15 |
The Scripps Research Institute |
Molekulare gewebesignaturen von nierentransplantatabstossungen
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
CA2949959A1
(en)
|
2014-05-22 |
2015-11-26 |
Northwestern University |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
EP3146076A4
(de)
|
2014-05-22 |
2018-05-09 |
The Scripps Research Institute |
Mit subklinischer nierentransplantatabstossung assoziierte genexpressionsprofile
|
CA2965153C
(en)
|
2014-10-20 |
2023-10-24 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2016100912A1
(en)
|
2014-12-18 |
2016-06-23 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2016164854A1
(en)
|
2015-04-09 |
2016-10-13 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP3294416A4
(de)
|
2015-05-12 |
2018-11-21 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
|
US11506672B2
(en)
|
2015-06-11 |
2022-11-22 |
Astute Medical, Inc. |
Follistatin-related protein 3 for diagnosis and prognosis of renal injury and renal failure
|
US20180224466A1
(en)
|
2015-06-17 |
2018-08-09 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
|
CN108291330A
(zh)
|
2015-07-10 |
2018-07-17 |
西弗吉尼亚大学 |
卒中和卒中严重性的标志物
|
US11192857B2
(en)
|
2016-05-18 |
2021-12-07 |
Alere San Diego, Inc. |
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
|
WO2017214203A1
(en)
|
2016-06-06 |
2017-12-14 |
Astute Medical, Inc. |
Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
WO2018067474A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing gfap status in patient samples
|
EP3522893A4
(de)
|
2016-10-04 |
2020-08-26 |
University Of Maryland, Baltimore |
Verfahren zur behandlung von sepsis unter verwendung von therapeutika auf der basis von anti-sepsis-lipid a (asla)
|
JP6633812B2
(ja)
|
2016-11-08 |
2020-01-22 |
リアタ ファーマシューティカルズ インコーポレイテッド |
バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法
|
EP3568695A4
(de)
|
2017-01-12 |
2020-12-16 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur bewertung und behandlung von nierenschäden und nierenversagen auf basis von c-c-motiv-chemokinligand-14-messung
|
WO2018164580A1
(en)
|
2017-03-09 |
2018-09-13 |
Rijksuniversiteit Groningen |
Biomarkers for cellular senescence
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
BR112019021612A2
(pt)
|
2017-04-15 |
2020-05-12 |
Abbott Laboratories |
Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
|
US10877038B2
(en)
|
2017-04-28 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JP2020519904A
(ja)
|
2017-05-07 |
2020-07-02 |
アスチュート メディカル,インコーポレイテッド |
腎代替療法の管理におけるインスリン様増殖因子結合タンパク質7および組織メタロプロテアーゼ阻害物質2の使用
|
CA3078725A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
AU2018275235A1
(en)
|
2017-05-30 |
2019-10-31 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
|
JP7454945B2
(ja)
|
2017-07-03 |
2024-03-25 |
アボット・ラボラトリーズ |
血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
|
WO2019113525A2
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
AU2018378084A1
(en)
|
2017-12-09 |
2020-05-14 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
EP3732196A4
(de)
|
2017-12-28 |
2022-01-05 |
Astute Medical, Inc. |
Antikörper und assays für ccl14
|
CA3084064A1
(en)
|
2017-12-29 |
2019-07-04 |
Abbott Laboratories |
Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
|
EP3788377A1
(de)
|
2018-05-04 |
2021-03-10 |
Abbott Laboratories |
Hbv-diagnostische, prognostische und therapeutische verfahren und produkte
|
EP4043015A1
(de)
|
2018-09-04 |
2022-08-17 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Delta-tocotrienol zur behandlung von krebs
|
CN113454455A
(zh)
|
2018-12-28 |
2021-09-28 |
雅培制药有限公司 |
微粒上的单分子的直接检测
|
WO2020144535A1
(en)
|
2019-01-08 |
2020-07-16 |
Aduro Biotech Holdings, Europe B.V. |
Methods and compositions for treatment of multiple myeloma
|
WO2020180695A1
(en)
|
2019-03-01 |
2020-09-10 |
Abbott Laboratories |
Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
EP4146226A1
(de)
|
2020-05-09 |
2023-03-15 |
Reata Pharmaceuticals Holdings, LLC |
Verfahren zur behandlung von covid-19 mit bardoxolonmethyl oder analoga davon
|
WO2021245025A1
(en)
|
2020-06-01 |
2021-12-09 |
Loop Diagnostics, S.L. |
Method and kit for the early detection of sepsis
|
JP2023536737A
(ja)
|
2020-08-04 |
2023-08-29 |
アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー |
Sars-cov-2を検出するためのアッセイ
|
CA3188349A1
(en)
|
2020-08-04 |
2022-02-10 |
A. Scott Muerhoff |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
WO2022099216A1
(en)
*
|
2020-11-09 |
2022-05-12 |
Children's Medical Center Corporation |
Systems and methods for high throughput screening of molecular interactions
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022126129A1
(en)
|
2020-12-11 |
2022-06-16 |
Reata Pharmaceuticals, Inc. |
Synthetic triterpenoids for use in therapy
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2023028186A1
(en)
|
2021-08-27 |
2023-03-02 |
Abbott Laboratories |
Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023144206A1
(en)
|
2022-01-27 |
2023-08-03 |
Sanofi Pasteur |
Modified vero cells and methods of using the same for virus production
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024059692A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|